Please Login to participate

Course HomeCourse Progress
  • Pre-Activity Survey
  • Webcast
  • Evaluation
  • Certificate

Practical Updates in Primary Care 2021 Q&A Review: Bipolar Disorder 360

Faculty

 
W. Clay Jackson, MD, DipTh
Clinical Assistant Professor of Psychiatry and Family Medicine
University of Tennessee College of Medicine
Memphis, Tennessee
 

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York
 
This activity includes questions that were submitted from attendees during the Practical Updates in Primary Care 2021 conference session titled, "Bipolar Disorder Across the Spectrum: Novel Screening Tools and Treatment Options". Please click here if you wish to watch that session on demand. 

Intended Learners

This conference is designed for primary care physicians, family medicine specialists, internists, pediatricians, nurse practitioners, nurses, physician assistants, pharmacists, registered dietitians, certified diabetes educators, and other related healthcare professionals involved in primary care.

Learning Objectives

After completing this activity, participants should be able to

  • Address the most frequently asked questions about bipolar disorder.

Claiming Credit

To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

Release Date: January 28, 2022
Expiration Date: January 28, 2023
Estimated Time to Complete: 20 minutes

There is no fee associated with this activity.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

Jointly Accredited ProviderIn support of improving patient care, HMP Global is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME

HMP Global designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CNE

This continuing nursing education activity awards .25 contact hour.

CPE

This activity is approved for .25 contact hour (0.025 CEU) of continuing pharmacy education (UAN JA0006201-0000-22-021-H04-P ).

This educational activity is a knowledge-based activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, HMP Education will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@hmpglobal.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers,  Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@hmpglobal.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.

Financial Disclosure and Conflicts of Interest

HMP Global is an independent provider of continuing medical education. HMP Global has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Global is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

  1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
  2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Global has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

  1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
  2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
  3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

FACULTY

The faculty has reported the following:

Joseph Goldberg: Consultant—BioXcel, Jazz Pharmaceuticals, Lundbeck, Medscape, Otsuka, Sage Pharmaceuticals, Sunovion, WebMD; Royalties—American Psychiatric Association Publishing, Inc., Cambridge University Press; Speakers Bureau—Alkermes, AbbVie, Intracellular Therapies, Sunovion

W. Clay Jackson: Consultant—AbbVie, Alkermes, Otsuka

Peter Oettgen has nothing to disclose in relation to this activity.

CLINICAL REVIEWER

Peter Oettgen
Preventive Cardiologist Cardiology Division Beth Israel Deaconess Medical Center

Associate Professor Harvard Medical School Boston, MA

Nurse Planner:  Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

PLANNING COMMITTEE

HMP Global planners and staff include Ms. Bielar, Ms. Browne, Ms. Conforti, Ms. Duda, Mr. Harper, Ms. Hines, Ms. Johnson,  Mr. Robbin, Mr. Sellers, and Ms. Tong

No HMP Global planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

Privacy Policy

HMP Global protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. HMP Global and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

HMP Global maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2022 by HMP Global. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Global.

Grant Support

This activity is supported by an independent educational grant from Alkermes, Inc. and Intra-Cellular Therapies, Inc.